Biomarkers of immunotherapy response in patients with allergic rhinitis

Amelia Licari, Riccardo Castagnoli, Ilaria Brambilla, Maria Angela Tosca, Maria De Filippo, Gianluigi Marseglia, Giorgio Ciprandi

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Allergen immunotherapy represents the only disease-modifying therapy available for immunoglobulin E-mediated diseases such as allergic rhinitis and asthma. Allergen immunotherapy induces allergen tolerance by interfering with the immune-pathogenic mechanisms of the allergic response and is potentially able to provide long-term relief of symptoms of allergic rhinitis and asthma and alter the natural course of allergic diseases. Areas covered: Since allergen immunotherapy (AIT) is actually considered an individualized treatment on patient's clinical and immunological profile, the identification of specific biomarkers, which may guide diagnosis, management, and predict response to AIT treatment in allergic rhinitis (AR) patients, is essential and is currently an active field of research. Expert commentary: The identification and validation of biomarkers of successful AIT for AR is an urgent need to definitively establish the role of AIT as a therapeutic tool of personalized medicine.

Original languageEnglish
Pages (from-to)657-663
Number of pages7
JournalExpert Review of Clinical Immunology
Volume14
Issue number8
DOIs
Publication statusPublished - Aug 2018

    Fingerprint

Cite this